High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL

J Immunol. 2001 Feb 1;166(3):1690-7. doi: 10.4049/jimmunol.166.3.1690.

Abstract

Previously, we observed that high-avidity CTL are much more effective in vivo than low-avidity CTL in elimination of infected cells, but the mechanisms behind their superior activity remained unclear. In this study, we identify two complementary mechanisms: 1) high-avidity CTL lyse infected cells earlier in the course of a viral infection by recognizing lower Ag densities than those distinguished by low-avidity CTL and 2) they initiate lysis of target cells more rapidly at any given Ag density. Alternative mechanisms were excluded, including: 1) the possibility that low-avidity CTL might control virus given more time (virus levels remained as high at 6 days following transfer as at 3 days) and 2) that differences in efficacy might be correlated with homing ability. Furthermore, adoptive transfer of high- and low-avidity CTL into SCID mice demonstrated that transfer of a 10-fold greater amount of low-avidity CTL could only partially compensate for their decreased ability to eliminate infected cells. Thus, we conclude that high-avidity CTL exploit two complementary mechanisms that combine to prevent the spread of virus within the animal: earlier recognition of infected cells when little viral protein has been made and more rapid lysis of infected cells.

Publication types

  • Comparative Study

MeSH terms

  • Adoptive Transfer
  • Animals
  • Antigen Presentation
  • Cell Line
  • Cell Movement / immunology
  • Clone Cells
  • Cytotoxicity Tests, Immunologic* / methods
  • Cytotoxicity, Immunologic*
  • Female
  • HIV Antigens / genetics
  • HIV Antigens / immunology
  • HIV Antigens / metabolism
  • HIV Envelope Protein gp160 / genetics
  • HIV Envelope Protein gp160 / immunology
  • HIV Envelope Protein gp160 / metabolism
  • Kinetics
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred DBA
  • Mice, SCID
  • Ovarian Diseases / immunology
  • Ovarian Diseases / virology
  • Peptide Fragments / genetics
  • Peptide Fragments / immunology
  • Peptide Fragments / metabolism
  • T-Lymphocyte Subsets / immunology*
  • T-Lymphocyte Subsets / metabolism
  • T-Lymphocyte Subsets / transplantation
  • T-Lymphocyte Subsets / virology*
  • T-Lymphocytes, Cytotoxic / immunology*
  • T-Lymphocytes, Cytotoxic / metabolism
  • T-Lymphocytes, Cytotoxic / transplantation
  • T-Lymphocytes, Cytotoxic / virology*
  • Tumor Cells, Cultured
  • Vaccinia / immunology
  • Vaccinia / virology
  • Vaccinia virus / genetics
  • Vaccinia virus / immunology
  • Viral Load

Substances

  • HIV Antigens
  • HIV Envelope Protein gp160
  • HIV-1 gp160 (315-329)
  • Peptide Fragments